Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.30 and traded as high as $1.67. Coherus Oncology shares last traded at $1.60, with a volume of 985,010 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CHRS shares. Weiss Ratings restated a “sell (d)” rating on shares of Coherus Oncology in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Coherus Oncology presently has an average rating of “Hold” and a consensus target price of $4.02.

Coherus Oncology Stock Performance

The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42. The stock has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.30. The firm has a market cap of $193.39 million, a price-to-earnings ratio of 1.20 and a beta of 0.96.

Coherus Oncology (NASDAQ:CHRS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $11.57 million for the quarter, compared to the consensus estimate of $13.41 million. As a group, analysts predict that Coherus Oncology, Inc. will post -1.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CHRS. Strs Ohio acquired a new stake in Coherus Oncology in the 1st quarter valued at about $261,000. Panagora Asset Management Inc. bought a new position in shares of Coherus Oncology during the second quarter worth approximately $581,000. International Assets Investment Management LLC acquired a new stake in shares of Coherus Oncology during the 2nd quarter worth $33,000. Quarry LP acquired a new position in shares of Coherus Oncology in the 3rd quarter valued at approximately $26,000. Finally, Focus Partners Wealth acquired a new stake in shares of Coherus Oncology in the 3rd quarter valued at $70,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.